Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Tethys BioScience

Founders David Hodgson Dr .Urdea Mickey S. Urdea


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 1
Average round size
The average size of a deal this fund participated in
Portfolio companies 1
Rounds per year 0.05
Lead investments 1
Key employees Soon

Areas of investment

  • Biotechnology
  • Biopharma
  • Health Care

Tethys BioScience appeared to be the Corporate Investor, which was created in 2002. The venture was found in North America in United States. The main office of represented Corporate Investor is situated in the Emeryville.

Among the various public portfolio startups of the fund, we may underline Theravectys Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - France. Among the most successful fund investment fields, there are Health Care, Biopharma.

The standard case for the fund is to invest in rounds with 1 partaker. Despite the Tethys BioScience, startups are often financed by Richard HENNESSY, Philippe ODDO, John PIETERS. In the next rounds fund is usually obtained by Bpifrance.

The important activity for fund was in 2013. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year.

The fund was created by David Hodgson, Dr .Urdea, Mickey S. Urdea.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
11-11 Ventures Alpharetta, Georgia, United States
Bridges Alliance Partners -
Brown Trust -
Cielo Talent Brookfield, United States, Wisconsin
Cineplex Entertainment Canada, Ontario, Toronto
Crescat Capital Colorado, Denver, United States
Dutch Founders Fund Amsterdam, Noord-Holland, The Netherlands
GO Ventures -
Gold Mountains Asset Management Co. Ltd China, Hong Kong, Kowloon
KES 7 Capital Canada, Ontario, Toronto
LifeArc England, London, United Kingdom
Neoplux Seoul, Seoul-t'ukpyolsi, South Korea
Qinhuangdao Aosheng Investment China, Hebei, Qinhuangdao
ReBoost Japan, Tokyo
Schwab Institutional California, San Francisco, United States
Tres Monos Capital -
Unlock Venture Partners Seattle, United States, Washington
Zhongtai Investment -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Health Care
$17M16 Oct 2013 Ile-de-France


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Tethys BioScience?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: